Researchers have developed a new imaging agent that could help guide and assess treatments for people with various neurological diseases, including Alzheimer's, Parkinson's and Multiple Sclerosis (MS).

The agent, which is used in PET scans, targets receptors in nerve cells in the brain that are involved in learning and memory.